<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Aprepitant</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00673</strong>&#160; (APRD00100)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00673/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00673/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00673.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00673.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00673.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00673.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00673.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00673">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Aprepitant</td><td>German/Spanish</td><td>INN</td></tr><tr><td>Apr&#233;pitant</td><td>French</td><td>INN</td></tr><tr><td>Aprepitantum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aprecap</td><td>Glenmark</td></tr><tr><td>Emend</td><td>Merck &amp; Co.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>170729-80-3</td></tr><tr><th>Weight</th><td>Average: 534.4267<br>Monoisotopic: 534.150187993</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>21</sub>F<sub>7</sub>N<sub>4</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>ATALOFNDEOCMKK-OITMNORJSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Oxazinanes</td></tr><tr><th>Subclass</th><td>Morpholines</td></tr><tr><th>Direct parent</th><td>Phenylmorpholines</td></tr><tr><th>Alternative parents</th><td>Benzylethers; Fluorobenzenes; Aryl Fluorides; Triazoles; Tertiary Amines; Dialkyl Ethers; Acetals; Polyamines; Alkyl Fluorides; Organofluorides</td></tr><tr><th>Substituents</th><td>benzylether; fluorobenzene; aryl halide; aryl fluoride; benzene; azole; 1,2,4-triazole; tertiary amine; acetal; polyamine; ether; dialkyl ether; organofluoride; organonitrogen compound; alkyl halide; alkyl fluoride; amine; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).</td></tr><tr><th>Pharmacodynamics</th><td>Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT<sub>3</sub>), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).</td></tr><tr><th>Mechanism of action</th><td>Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT<sub>3</sub>-receptor antagonist ondansetron and the corticosteroid
ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis.</td></tr><tr><th>Absorption</th><td>The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>70 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>&gt;95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Aprepitant</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00349">(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/351">Details</a></td></tr><tr><td>Aprepitant</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00474">5-({[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}methyl)-2,3-dihydro-1H-1,2,4-triazol-3-one</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/483">Details</a></td></tr><tr><td>Aprepitant</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00475">(2R)-2-(4-fluorophenyl)-2-{[(5-oxo-2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]amino}acetic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/484">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.</td></tr><tr><th>Half life</th><td>9-13 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>Apparent plasma cl=62-90 mL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9952</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.5588</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6237</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8106</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5243</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9564</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7444</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.788</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6461</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6012</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.535</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.84</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5862</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.8396</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5758
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8152
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6055 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6598
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8163
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Merck and co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Aprepitant may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Aprepitant may increase the effect and toxicity of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The CYP3A4 inhibitor, clarithromycin, may increase the effect and toxicity of aprepitant.</td></tr><tr><td><a href="/drugs/DB01285">Corticotropin</a></td><td>Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>Aprepitant may increase the effect and toxicity of dexamethasone.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB01248">Docetaxel</a></td><td>Aprepitant may change levels of the chemotherapy agent, docetaxel.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Aprepitant could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB00773">Etoposide</a></td><td>Aprepitant may change levels of the chemotherapy agent, etoposide.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB01181">Ifosfamide</a></td><td>Aprepitant may change levels of the chemotherapy agent, ifosfamide.</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Aprepitant may change levels of the chemotherapy agent, imatinib.</td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>Aprepitant may change levels of the chemotherapy agent, irinotecan.</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>The CYP3A4 inducer, mephenytoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Aprepitant could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>Increases the effect and toxicity of methylprednisolone</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Aprepitant may change levels of the chemotherapy agent, paclitaxel.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Aprepitant may increase the effect and toxicity of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB01361">Troleandomycin</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Aprepitant may change levels of the chemotherapy agent, vinblastine. </td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Aprepitant may change levels of the chemotherapy agent, vincristine.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Aprepitant may change levels of the chemotherapy agent, vinorelbine.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>